Protalix BioTherapeutics, Inc. Share Price
PLXProtalix BioTherapeutics, Inc. Stock Performance
Open $2.00 | Prev. Close $1.96 | Circuit Range N/A |
Day Range $1.98 - $2.02 | Year Range $1.32 - $3.19 | Volume 15,475 |
Average Traded $2.00 |
Protalix BioTherapeutics, Inc. Share Price Chart
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Protalix BioTherapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
09-Jun-26 | $2.00 | $1.97 | +0.00% |
09-Jun-26 | $2.00 | $1.97 | +0.26% |
08-Jun-26 | $2.00 | $1.96 | -1.26% |
05-Jun-26 | $2.00 | $1.99 | -0.75% |
04-Jun-26 | $1.96 | $2.00 | +2.56% |
03-Jun-26 | $1.98 | $1.95 | -2.26% |
02-Jun-26 | $1.99 | $2.00 | -3.16% |